No­var­tis, Eli Lil­ly mar­quee pos­i­tive sur­vival da­ta for CDK 4/6 fran­chis­es — but can they ac­tu­al­ly beat Pfiz­er's block­buster?

BARCELONA — A lit­tle more than a year af­ter Pfiz­er’s big CDK 4/6 can­cer drug block­buster Ibrance failed to hit the mark in over­all sur­vival, two big ri­vals are knock­ing on their front door bear­ing da­ta from two Phase III stud­ies clear­ly show­ing that their ri­val treat­ments can sig­nif­i­cant­ly ex­tend the lives of pa­tients.

Re­search teams for both turned up at ES­MO over the week­end with promis­ing OS re­sults in ad­vanced breast can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER